Kaléo Pharmaceuticals has dramatically increased the cost of an easy-to-use injection device for the opioid overdose reversal drug known as naloxone, and lawmakers believe the price hike could put lives at risk.
US Senator Kirsten Gillibrand (D-New York) and 31 other senators issued a stinging rebuke and call for answers on February 8 after the details of the price increase emerged.
The device, known as Evzio, was listed at $690 in 2014. It now reportedly costs $4,500. The drug company has previously said that it is increasing prices on products to meet the rising costs of manufacturing.
While it is true that naloxone has increased in price — now somewhere around $150 per 10cc vial — the senators pointed out that this does not come anywhere close to the near 700 percent increase on Evzio instituted by the company.
“At a time when Congress has worked to expand access to naloxone products and to assist state and local communities to equip first responders with this life-saving drug, this startling price hike is very concerning,” the senators wrote in a letter to Kaléo Pharmaceuticals CEO Spencer Williamson.
As is standard for this kind of product, the company has provided free devices to first responders and drug treatment programs. Despite this gesture, Forbes notes:
With the supply of Evzio now depleted since last July, and patients often unable to afford the device if their insurance doesn’t participate to give them a $0 copay as they have advertised, the public will be left scrambling, just as occurred with the EpiPen drama this past fall.
In the letter, senators ask three specific questions of Kaléo. They ask the firm to clearly demonstrate its pricing structure and how it justifies this price increase, to quantify how many products it sets aside for donation and how it has informed customers of its donation programs and to reveal the “total amount Evzio received in reimbursements from the federal government in the past 12 months.”
This latter point is a crucial one, as lawmakers have consistently argued that they should not — and will not — provide incentives, reimbursements or advantageous to firms that make massive profits from treating sick people.
As Care2 has previously explored, the opioid crisis represents an ongoing problem for the United States, and recent figures suggest that more than 52,000 people died from opioid overdose in 2015.
There is plenty of evidence to show that naloxone kits, when affordable, are an effective means of preventing opioid overdose deaths. However, insurers have indicated that, as with other drugs, they may no longer cover this vital overdose reversal drug because they simply cannot absorb increased cost.
Senators have begun to examine pharmaceutical pricing with increasing scrutiny, from the Turing Pharmaceuticals debacle of a few years ago to the ongoing issue of the EpiPen price hike that has left many parents distressed and scrambling for alternatives for their children.
Of course, drug firms are correct in saying that they must price competitively and with a mind to future development — however that is not what appears to be happening in some cases.
Rather, certain companies seem to be using US law to ensure they are the only ones who can market key products. After an initial marketing period featuring low prices — at which point the drug becomes the go-to option for consumers — the company then raises the cost, often several times over.
This kind of practice is not only deeply disturbing in terms of business operations — competitive pricing should provide lower costs to consumers — but it is also ethically troubling. People may not be able to afford life-saving medicines.
In a separate but politically relevant comment, Senator Angus King noted his puzzlement as to why no Republican lawmakers signed the letter. In the past, issues involving pharmaceutical industry practices have garnered bipartisan support. King has said he always aims to cultivate both Republican and Democratic support in these circumstances to show that this is not a political issue, but rather one of fair treatment for consumers.
While it could simply be a matter of outrage fatigue as lawmakers have repeatedly pressed companies to justify price hikes, a lack of Republican support this time around may highlight the Trump administration’s impact. Trump heavily supports further deregulation, which could exacerbate what lawmakers have called “outrageous” price hikes.
A lack of congressional action on this issue would be a bitter pill to swallow and threatens to leave consumers at the mercy of price gouging.
We’re not backing down in the face of Trump’s threats.
As Donald Trump is inaugurated a second time, independent media organizations are faced with urgent mandates: Tell the truth more loudly than ever before. Do that work even as our standard modes of distribution (such as social media platforms) are being manipulated and curtailed by forces of fascist repression and ruthless capitalism. Do that work even as journalism and journalists face targeted attacks, including from the government itself. And do that work in community, never forgetting that we’re not shouting into a faceless void – we’re reaching out to real people amid a life-threatening political climate.
Our task is formidable, and it requires us to ground ourselves in our principles, remind ourselves of our utility, dig in and commit.
As a dizzying number of corporate news organizations – either through need or greed – rush to implement new ways to further monetize their content, and others acquiesce to Trump’s wishes, now is a time for movement media-makers to double down on community-first models.
At Truthout, we are reaffirming our commitments on this front: We won’t run ads or have a paywall because we believe that everyone should have access to information, and that access should exist without barriers and free of distractions from craven corporate interests. We recognize the implications for democracy when information-seekers click a link only to find the article trapped behind a paywall or buried on a page with dozens of invasive ads. The laws of capitalism dictate an unending increase in monetization, and much of the media simply follows those laws. Truthout and many of our peers are dedicating ourselves to following other paths – a commitment which feels vital in a moment when corporations are evermore overtly embedded in government.
Over 80 percent of Truthout‘s funding comes from small individual donations from our community of readers, and the remaining 20 percent comes from a handful of social justice-oriented foundations. Over a third of our total budget is supported by recurring monthly donors, many of whom give because they want to help us keep Truthout barrier-free for everyone.
You can help by giving today. Whether you can make a small monthly donation or a larger gift, Truthout only works with your support.